Beclabuvir

• Description :

  Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of [1][2].

• Product Name Alternative :

  BMS-791325

• UNSPSC :

  12352005

• Target :

  HCV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/Beclabuvir.html

• Concentration :

  10mM

• Purity :

  99.94

• Solubility :

  DMSO : ≥ 30 mg/mL

• Smiles :

  O=C(N1C2CCC1CN(C)C2)[C@@]3(CN4C5=C(C6CCCCC6)C7=CC=C(C(NS(=O)(N(C)C)=O)=O)C=C47)[C@H](C8=CC(OC)=CC=C85)C3

• Molecular Formula :

  C36H45N5O5S

• Molecular Weight :

  659.84

• References & Citations :

  [1]Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24 (8) :1111-21|[2]Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22 (8) :658-64.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 4

• CAS Number :

  [958002-33-0]